Aberrant promoter methylation of multiple genes in non-small cell lung cancers.

By S. Zöchbauer-Müller, K. Fong, A. Virmani, J. Geradts, Adi F. Gazdar, J. Minna. Cancer Research, 2001

630 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future (2002, background): “We can call this the ‘Methylotype’, for the sake of analogy with the genetic term ‘Genotype’ (such as Zochbauer-Muller et al., 2001a; Eads et al., 2001).”
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. (2001, methodology): “Genomic DNAs from lung cancer cell lines not expressing RASSF1A (NCI lines H1299, H1184, H1304, H841, H2108, and H128) or expressing RASSF1A (H1792 and H2009) were modified by sodium bisulfite treatment as described previously (24, 25 ).”
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets (2007, methodology): “DNA methylation at CDH1 and CDKN2A promoter was assessed for using bisulfite DNA and methylation specific amplification as previously described(15, 16).”